A068270 Stock Overview
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea.
No risks detected for A068270 from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||₩141,000.00|
|52 Week High||₩294,607.84|
|52 Week Low||₩139,000.00|
|1 Month Change||-11.60%|
|3 Month Change||-10.48%|
|1 Year Change||-46.44%|
|3 Year Change||-14.90%|
|5 Year Change||70.85%|
|Change since IPO||1,264.28%|
Recent News & Updates
|A068270||KR Biotechs||KR Market|
Return vs Industry: A068270 underperformed the KR Biotechs industry which returned -38% over the past year.
Return vs Market: A068270 underperformed the KR Market which returned -14.6% over the past year.
|A068270 Average Weekly Movement||6.0%|
|Biotechs Industry Average Movement||6.6%|
|Market Average Movement||5.6%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A068270 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A068270's weekly volatility (6%) has been stable over the past year.
About the Company
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial.
Celltrion Fundamentals Summary
|A068270 fundamental statistics|
Is A068270 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A068270 income statement (TTM)|
|Cost of Revenue||₩810.18b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||4.14k|
|Net Profit Margin||30.08%|
How did A068270 perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Celltrion undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A068270 (₩141000) is trading below our estimate of fair value (₩199507.45)
Significantly Below Fair Value: A068270 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A068270 is poor value based on its PE Ratio (34.1x) compared to the KR Biotechs industry average (25.4x).
PE vs Market: A068270 is poor value based on its PE Ratio (34.1x) compared to the KR market (14.4x).
Price to Earnings Growth Ratio
PEG Ratio: A068270 is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: A068270 is overvalued based on its PB Ratio (5x) compared to the KR Biotechs industry average (3.3x).
How is Celltrion forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A068270's forecast earnings growth (14.7% per year) is above the savings rate (3.5%).
Earnings vs Market: A068270's earnings (14.7% per year) are forecast to grow slower than the KR market (14.8% per year).
High Growth Earnings: A068270's earnings are forecast to grow, but not significantly.
Revenue vs Market: A068270's revenue (13.5% per year) is forecast to grow faster than the KR market (9.6% per year).
High Growth Revenue: A068270's revenue (13.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A068270's Return on Equity is forecast to be low in 3 years time (16.5%).
How has Celltrion performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A068270 has high quality earnings.
Growing Profit Margin: A068270's current net profit margins (30.1%) are higher than last year (27.7%).
Past Earnings Growth Analysis
Earnings Trend: A068270's earnings have grown by 17.7% per year over the past 5 years.
Accelerating Growth: A068270's earnings growth over the past year (12.5%) is below its 5-year average (17.7% per year).
Earnings vs Industry: A068270 earnings growth over the past year (12.5%) underperformed the Biotechs industry 37.5%.
Return on Equity
High ROE: A068270's Return on Equity (14.5%) is considered low.
How is Celltrion's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A068270's short term assets (₩3,076.9B) exceed its short term liabilities (₩1,210.5B).
Long Term Liabilities: A068270's short term assets (₩3,076.9B) exceed its long term liabilities (₩413.3B).
Debt to Equity History and Analysis
Debt Level: A068270 has more cash than its total debt.
Reducing Debt: A068270's debt to equity ratio has reduced from 30.9% to 18.1% over the past 5 years.
Debt Coverage: A068270's debt is well covered by operating cash flow (123.6%).
Interest Coverage: A068270's interest payments on its debt are well covered by EBIT (195.9x coverage).
What is Celltrion current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A068270's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (0.84%).
High Dividend: A068270's dividend (0.52%) is low compared to the top 25% of dividend payers in the KR market (2.75%).
Stability and Growth of Payments
Stable Dividend: A068270's dividend payments have been volatile in the past 10 years.
Growing Dividend: A068270's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (17.8%), A068270's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (16.5%), A068270's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Hyong-Gi Kim (56 yo)
Mr. Hyong-Gi Kim serves as Chief Executive Officer at Celltrion, Inc. Mr. Kim served as Vice President of Celltrion Pharm Inc. He served as Head of Strategy and Planning Team, Daewoo Motor Company. He serv...
Experienced Board: A068270's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Celltrion, Inc.'s employee growth, exchange listings and data sources
- Name: Celltrion, Inc.
- Ticker: A068270
- Exchange: KOSE
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩19.584t
- Shares outstanding: 138.90m
- Website: https://www.celltrion.com
Number of Employees
- Celltrion, Inc.
- 23 Academy-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.